Hyderabad: Development of myeloid leukemia is a rare adverse effect which has been found to be caused by the toxicity of drugs and drug combinations used for chemotherapy to treat cancer.
The study published in JAMA Oncology analysed clinical cancer outcomes from 2000 to 2014 and found that the development of rare cancers after the treatment occurred after a year.
With the advances in treatment there are improved survival rates in many types of cancers but the increased risk of treatment-related cancers is also being noted.
Myeloid leukemia is a rare but fatal blood cancer and was recorded in patients who had solid tumours.
The study found that 1,619 patients developed leukemia after a gap of one-and-a-half years. The controlled clinical trials on these patients showed that the adverse effect was due to the treatment using toxic combinations that they had received for the treatment of cancers in the ovary, lung, breast, soft tissues, testis, brain and the central nervous systems.
Dr C. Srinivas, senior oncologist, explained, “The side-effects of chemotherapy have been recorded but the development of a rare cancer like leukemia can be found only in one in 1,000 patients. We need more studies to back the data.”
The re-emergence of the same cancer is possible stated experts. Dr Geeta Narsagree, senior oncologist said, “The option of surgery along with oral chemotherapy is being opted for as the side-effects can be controlled. With robotic technology, there are tumours which can be removed and these help understand the spread of the cancer. Accordingly aggressive treatment methods can be reduced.”
The new treatment methods of targeted therapy and also immunotherapy are being opted as it will help the patients have an improved quality of life as survivors and not suffer from the side-effects of treatment....